Pfizer (NYSE:PFE) Stock Price Up 1.3% - Here's Why

Key Points

• Pfizer shares rose 1.3% on Thursday, with trading volume slightly above average as investors reacted to recent company news.
• FDA approval for a new PADCEV plus Keytruda bladder cancer regimen is a major positive, expanding Pfizer’s oncology portfolio and supporting its growth outlook.
• Pfizer remains a mixed-to-neutral Wall Street story: analysts largely rate the stock a Hold, while the company also faces some overhangs such as supply challenges for Premarin in India and legal action related to mRNA patent technology.

Pfizer Inc. (NYSE:PFE - Get Free Report) traded up 1.3% on Thursday . The stock traded as high as $25.37 and last traded at $25.1330. 44,405,299 shares changed hands during trading, an increase of 4% from the average session volume of 42,627,141 shares. The stock had previously closed at $24.82.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer received FDA approval for a new PADCEV plus Keytruda regimen in muscle-invasive bladder cancer, expanding the combination’s use as both neoadjuvant and adjuvant therapy and strengthening Pfizer’s oncology growth story. Pfizer (PFE) Wins FDA Approval For First Platinum Free Bladder Cancer Regimen
• Positive Sentiment: Analysts and market commentary continue to point to upside potential, with Pfizer still viewed as inexpensive relative to earnings and offering a high dividend, which may support the stock despite recent weakness. Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?
• Neutral Sentiment: Several articles framed Pfizer’s shares as fairly priced or in a valuation “middle ground,” suggesting the market is still weighing pipeline progress against longer-term risks rather than assigning a clear premium or discount. Pfizer (PFE) Stock Looks Fairly Priced With Pipeline Risks In View
• Neutral Sentiment: Arbutus Biopharma filed international patent lawsuits against Pfizer and BioNTech over lipid nanoparticle technology used in mRNA vaccines. While this introduces legal overhang, the financial impact remains uncertain at this stage. Reuters: Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges
• Negative Sentiment: Pfizer also said it suspended sales of Premarin vaginal cream in India because of supply challenges, which could be seen as a small setback in an already closely watched portfolio. Reuters: Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

Analyst Ratings Changes

PFE has been the subject of several recent research reports. UBS Group reiterated a "neutral" rating and issued a $27.00 price objective on shares of Pfizer in a research note on Wednesday, May 27th. JPMorgan Chase & Co. reduced their target price on shares of Pfizer from $30.00 to $28.00 and set a "neutral" rating on the stock in a report on Wednesday, July 8th. Wolfe Research reiterated an "underperform" rating and issued a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. Royal Bank Of Canada upgraded shares of Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price target for the company in a report on Tuesday, June 9th. Finally, BMO Capital Markets dropped their price objective on shares of Pfizer from $34.00 to $30.00 and set an "outperform" rating on the stock in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, Pfizer has an average rating of "Hold" and an average price target of $28.50.

Pfizer Stock Performance

The firm has a fifty day simple moving average of $25.25 and a 200-day simple moving average of $26.18. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The company has a market cap of $143.24 billion, a PE ratio of 19.19 and a beta of 0.35.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The firm had revenue of $14.45 billion during the quarter, compared to analysts' expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business's revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. Pfizer's dividend payout ratio (DPR) is 131.30%.

Institutional Trading of Pfizer

Several institutional investors and hedge funds have recently bought and sold shares of the business. Horizon Financial Services LLC boosted its stake in shares of Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 645 shares during the period. Godfrey Financial Associates Inc. acquired a new position in Pfizer in the 4th quarter valued at about $26,000. Keb Asset Management LLC acquired a new position in Pfizer in the 2nd quarter valued at about $26,000. YANKCOM Partnership purchased a new stake in Pfizer during the 4th quarter valued at approximately $28,000. Finally, HFM Investment Advisors LLC raised its stake in Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 427 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.